- SOHO 2023
- SOHO 2022
- SOHO 2021
- SOHO 2020
- SOHO Highlights: State of the Art and Next Questions
-
SOHO 2019
Hodgkin Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Meet The Professor Sessions Chronic Myeloid Leukemia Myeloproliferative Neoplasms Breakfast With The Expert Independent Satellite Symposium Plenary Sessions Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options Acute Lymphoblastic Leukemia Myelodysplastic Syndromes Acute Myeloid Leukemia Indolent B-cell Lymphoma Mantle Cell Lymphoma Aggressive B-cell Lymphoma T-cell Lymphoma Cellular Therapy Next Questions
-
SOHO 2018
Session I: Chronic Myeloid Leukemia Session II: Myelodysplastic Syndromes Session III: Myeloproliferative Neoplasms Session IV: Acute Lymphoblastic Leukemia Session V: Acute Myeloid Leukemia Session VI: Multiple Myeloma Session VIII: Non-Hodgkin Lymphoma Session IX: Chronic Lymphocytic Leukemia Session X: Research Topics Plenary Sessions Breakfast with the Expert
- Events
Playback speed
10 seconds
HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Younger AML Patients with Adverse Biology Routinely Receive It?
41 views
October 18, 2019
Comments 0
Login to view comments.
Click here to Login
Acute Myeloid Leukemia